Cancer immunotherapy Authors Stefano Vella Direttore, Dipartimento del Farmaco, Istituto Superiore di Sanità, Roma - Italy DOI: https://doi.org/10.33393/grhta.2016.305 Keywords: Immunoterapia, Cancer Abstract No abstract
Downloads PDF (Italian) ePub How to Cite Vella, S. (2019). Cancer immunotherapy. Global and Regional Health Technology Assessment, 3(Suppl. 1), S1-S2. https://doi.org/10.33393/grhta.2016.305 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Vol. 3 No. Suppl. 1 (2016): Suppl. 1 - Farmaci oncologici e sostenibilità Section Editorial (on invitation only) License Copyright (c) 2019 The authors This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Metrics Statistics Abstract views - 644 times PDF (Italian) downloads - 580 times ePub downloads - 236 times Sign up Browse Sections Health Technology Assessment Health Policies banners150 0.8 2023CiteScore 28th percentile Powered by Completed peer reviews since:November 4, 2020 Most popular articles in the last 30 days Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy 230 Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices 217 Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals 196 Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA) 191 Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL) 188